These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Kawashima H ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535 [TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Tomblyn M Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895 [TBL] [Abstract][Full Text] [Related]
7. [Radiolabeled antibodies for cancer treatment]. Barbet J; Chatal JF; Kraeber-Bodéré F Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676 [TBL] [Abstract][Full Text] [Related]
9. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model. Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949 [TBL] [Abstract][Full Text] [Related]
10. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Sharkey RM; Goldenberg DM J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660 [TBL] [Abstract][Full Text] [Related]
11. Status of radioimmunotherapy in the new millennium. Imam SK Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Dillman RO Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152 [TBL] [Abstract][Full Text] [Related]
14. Whither Radioimmunotherapy: To Be or Not To Be? Green DJ; Press OW Cancer Res; 2017 May; 77(9):2191-2196. PubMed ID: 28428282 [TBL] [Abstract][Full Text] [Related]
15. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052 [TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986 [TBL] [Abstract][Full Text] [Related]
17. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366 [TBL] [Abstract][Full Text] [Related]